173 related articles for article (PubMed ID: 12786889)
1. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.
Umekita Y; Yoshida H
Histopathology; 2003 Jun; 42(6):541-5. PubMed ID: 12786889
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: an immunohistochemical study.
Umekita Y; Yoshida H
Pathol Int; 2000 Jul; 50(7):527-30. PubMed ID: 10886733
[TBL] [Abstract][Full Text] [Related]
3. Expression of maspin predicts poor prognosis in breast-cancer patients.
Umekita Y; Ohi Y; Sagara Y; Yoshida H
Int J Cancer; 2002 Aug; 100(4):452-5. PubMed ID: 12115529
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of tumor suppressor gene maspin in breast cancer.
Maass N; Nagasaki K; Ziebart M; Mundhenke C; Jonat W
Clin Breast Cancer; 2002 Oct; 3(4):281-7. PubMed ID: 12425757
[TBL] [Abstract][Full Text] [Related]
5. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
6. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.
Kunju LP; Ding Y; Kleer CG
Pathol Int; 2008 Oct; 58(10):620-5. PubMed ID: 18801081
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of maspin expression in breast cancer.
Lee MJ; Suh CH; Li ZH
J Korean Med Sci; 2006 Apr; 21(2):309-14. PubMed ID: 16614520
[TBL] [Abstract][Full Text] [Related]
8. Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast.
Maass N; Teffner M; Rösel F; Pawaresch R; Jonat W; Nagasaki K; Rudolph P
J Pathol; 2001 Oct; 195(3):321-6. PubMed ID: 11673829
[TBL] [Abstract][Full Text] [Related]
9. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
10. Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer.
Kim DH; Yoon DS; Dooley WC; Nam ES; Ryu JW; Jung KC; Park HR; Sohn JH; Shin HS; Park YE
Histopathology; 2003 Jan; 42(1):37-42. PubMed ID: 12493023
[TBL] [Abstract][Full Text] [Related]
11. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
12. Ductal carcinoma in situ-like structures in metastatic breast carcinoma.
Kordek R
Pathol Res Pract; 2005; 200(11-12):831-4. PubMed ID: 15792128
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines.
Prasad CP; Rath G; Mathur S; Bhatnagar D; Ralhan R
Chem Biol Interact; 2010 Feb; 183(3):455-61. PubMed ID: 19944674
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study.
Umekita Y; Takasaki T; Yoshida H
Virchows Arch; 1994; 424(5):491-4. PubMed ID: 7913368
[TBL] [Abstract][Full Text] [Related]
15. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
[TBL] [Abstract][Full Text] [Related]
16. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
18. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas.
Ohike N; Maass N; Mundhenke C; Biallek M; Zhang M; Jonat W; Lüttges J; Morohoshi T; Klöppel G; Nagasaki K
Cancer Lett; 2003 Sep; 199(2):193-200. PubMed ID: 12969792
[TBL] [Abstract][Full Text] [Related]
20. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
